tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: Becton Dickinson (BDX) and Abiomed (ABMD)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Becton Dickinson (BDXResearch Report) and Abiomed (ABMDResearch Report).

Becton Dickinson (BDX)

Morgan Stanley analyst Drew Ranieri maintained a Buy rating on Becton Dickinson yesterday and set a price target of $310.00. The company’s shares closed last Friday at $268.85, close to its 52-week high of $272.36.

According to TipRanks.com, Ranieri is a 1-star analyst with an average return of -5.4% and a 37.0% success rate. Ranieri covers the Healthcare sector, focusing on stocks such as Treace Medical Concepts, Zimmer Biomet Holdings, and Baxter International.

Becton Dickinson has an analyst consensus of Moderate Buy, with a price target consensus of $283.29, which is a 6.1% upside from current levels. In a report issued on February 3, Stifel Nicolaus also maintained a Buy rating on the stock with a $318.00 price target.

See today’s best-performing stocks on TipRanks >>

Abiomed (ABMD)

In a report released yesterday, Cecilia Furlong from Morgan Stanley maintained a Sell rating on Abiomed, with a price target of $275.00. The company’s shares closed last Friday at $295.65.

According to TipRanks.com, Furlong is a 4-star analyst with an average return of 25.2% and a 46.3% success rate. Furlong covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Irhythm Technologies, and Edwards Lifesciences.

The word on The Street in general, suggests a Hold analyst consensus rating for Abiomed with a $370.00 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on BDX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos
---

Latest News Feed